STAAR Surgical Generates Cash From Operations During Seco...(----- ---- ----- ---- Net ...),Health

Date:8/3/2009

----- ---- ----- ---- Net sales 100% $19,117 100% $20,665 Cost of sales 44% 8,453 44% 9,131 ----- ----- Gross profit 56% 10,664 56% 11,534 ------ ------ Selling, general and administrative expenses: General and administrative 20% 3,855 17% 3,520 Marketing and selling 32% 6,032 37% 7,646 Research and development 8% 1,441 11% 2,357 Loss on settlement of pre-existing distribution arrangement 0% - 0% 0 --- --- Total selling, general and administrative expenses: 59% 11,328 65% 13,523 ------ ------ Operating loss -3% (664) -10% (1,989) ---- ------ Other income (expense): Interest income 0% 5 0% 63 Interest expense -2% (399) -1% (222) Gain on foreign currency 1% 122 0% 16 Other income, net 1% 128 0% (17) --- ---- Other (expense) income, net -1% (144) -1% (160) --- ---- Loss before provision for income taxes -4% (808) -10% (2,149) Provisio
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine news :

1. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
2. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
5. Richard A. Meier Appointed to STAAR Surgical Board of Directors
6. STAAR Surgical Completes Common Stock Offering
7. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
8. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
9. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
10. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
11. STAAR Surgical Reports 33% Third Quarter Revenue Growth